Influenza virus vaccines: Lessons from the 2009 H1N1 pandemic

Current Opinion in Virology

Volumn 1, Issue 4, 2011, Pages 254-262

  Broadbent, Andrew J ^a   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AS 03; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MIFAMURTIDE; UNCLASSIFIED DRUG; WATER OIL CREAM;

2009 H1N1 INFLUENZA; ANAPHYLAXIS; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE CONVULSION; GROUPS BY AGE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MYALGIA; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT OUTCOME; VACCINATION REACTION; VACCINE PRODUCTION;

EID: 80053375600     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2011.08.002     Document Type: Review

References (60)

1. P. Palese, and M. Shaw Orthomyxoviridae: the viruses and their replication D. Knipe, D. Griffin, R. Lamb, S. Straus, P. Howley, M. Martin, B. Roizman, Fields Viroloy vol 2 2007 Lippincott Williams & Wilkins Wolters Kluwer 1647 1689
2. P. Wright, G. Neumann, and Y. Kawaoka Orthomyxoviruses D. Knipe, D. Griffin, R. Lamb, S. Straus, P. Howley, M. Martin, B. Roizman, Fields Viroloy vol 2 2007 Lippincott Williams & Wilkins Wolters Kluwer 1691 1740
3. M.P. Girard, J.S. Tam, O.M. Assossou, and M.P. Kieny The 2009 A (H1N1) influenza virus pandemic: a review Vaccine 28 2010 4895 4902
4. N.J. Cox, and K. Subbarao Influenza Lancet 354 1999 1277 1282 (Pubitemid 29469365)
5. K.L. Nichol, and J.J. Treanor Vaccines for seasonal and pandemic influenza J Infect Dis 194 Suppl. 2 2006 S111 S118
6. E.D. Kilbourne Future influenza vaccines and the use of genetic recombinants Bull World Health Organ 41 1969 643 645
7. H.F. Maassab Adaptation and growth characteristics of influenza virus at 25 degrees C Nature 213 1967 612 614
8. World now at the start of 2009 influenza pandemic on World Wide Web URL: http://www.who.int/mediacentre/news/statements/2009/h1n1-pandemic-phase6- 20090611/en/index.html.
9. F.S. Dawood, S. Jain, L. Finelli, M.W. Shaw, S. Lindstrom, R.J. Garten, L.V. Gubareva, X. Xu, C.B. Bridges, and T.M. Uyeki Emergence of a novel swine-origin influenza A (H1N1) virus in humans N Engl J Med 360 2009 2605 2615
10. R.J. Garten, C.T. Davis, C.A. Russell, B. Shu, S. Lindstrom, A. Balish, W.M. Sessions, X. Xu, E. Skepner, and V. Deyde Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans Science 325 2009 197 201
11. G.J. Smith, D. Vijaykrishna, J. Bahl, S.J. Lycett, M. Worobey, O.G. Pybus, S.K. Ma, C.L. Cheung, J. Raghwani, and S. Bhatt Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic Nature 459 2009 1122 1125
12. S. Jain, L. Kamimoto, A.M. Bramley, A.M. Schmitz, S.R. Benoit, J. Louie, D.E. Sugerman, J.K. Druckenmiller, K.A. Ritger, and R. Chugh Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009 N Engl J Med 361 2009 1935 1944
13. D.J. Jamieson, M.A. Honein, S.A. Rasmussen, J.L. Williams, D.L. Swerdlow, M.S. Biggerstaff, S. Lindstrom, J.K. Louie, C.M. Christ, and S.R. Bohm H1N1 2009 influenza virus infection during pregnancy in the USA Lancet 374 2009 451 458
14. S.E. Lapinsky Critical illness as a result of influenza A/H1N1 infection in pregnancy BMJ 340 2010 c1235
15. J.S. Peiris, L.L. Poon, and Y. Guan Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans J Clin Virol 45 2009 169 173
16. L.C. Lambert, and A.S. Fauci Influenza vaccines for the future N Engl J Med 363 2010 2036 2044
17. D.M. Skowronski, N.Z. Janjua, G. De Serres, T.S. Hottes, J.A. Dickinson, N. Crowcroft, T.L. Kwindt, P. Tang, H. Charest, and K. Fonseca Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009 BMJ 342 2011 c7297
18. G.M. Leung, and Nicoll A Reflections on pandemic (H1N1) 2009 and the international response PLoS Med 2010 7
19. E. Prieto-Lara, and A. Llanos-Mendez Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature Vaccine 28 2010 4328 4334
20. K.M. Boyer, J.D. Cherry, P.F. Wright, S.J. Lerman, P.A. Gross, H.M. Foy, J.W. Taylor, and G.R. Noble Clinical reactions and serologic responses in healthy children aged six to 35 months after two-dose regimens of inactivated A/New Jersey/76 influenza virus vaccines J Infect Dis 136 Suppl. 1977 S579 S583
21. R. Dolin, T.G. Wise, M.H. Mazur, C.U. Tuazon, and F.A. Ennis Immunogenicity and reactogenicity of influenza A/New Jersey/76 virus vaccines in normal adults J Infect Dis 136 Suppl. 1977 S435 S442
22. L.T. Gutman, C.M. Wilfert, Z.H. Idriss, E. Schmidt, S. Andrews, and S.L. Katz Single-dose trials of monovalent A/New Jersey/76 (Hsw1N1) influenza virus vaccine in children in Durham, North Carolina J Infect Dis 136 Suppl. 1977 S575 S578
23. M.M. Levine, T.P. Hughes, P. Simon, S. O'Donnell, S. Grauel, and S.G. Levine Monovalent inactivated A/New Jersey/8/76 (Hsw1N1) vaccine in healthy children aged three to five years J Infect Dis 136 Suppl. 1977 S571 S574
24. G. Meiklejohn, T.C. Eickhoff, and P. Graves Antibody response of young adults to experimental influenza A/New Jersey/76 virus vaccines J Infect Dis 136 Suppl. 1977 S456 S459
25. FDA Guidance for Industry Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines 2007 DHHS Rockville 1-18
26. D. Hobson, R.L. Curry, A.S. Beare, and A. Ward-Gardner The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses J Hyg (Lond) 70 1972 767 777
27. M.E. Greenberg, M.H. Lai, G.F. Hartel, C.H. Wichems, C. Gittleson, J. Bennet, G. Dawson, W. Hu, C. Leggio, and D. Washington Response to a monovalent 2009 influenza A (H1N1) vaccine N Engl J Med 361 2009 2405 2413
28. X.F. Liang, H.Q. Wang, J.Z. Wang, H.H. Fang, J. Wu, F.C. Zhu, R.C. Li, S.L. Xia, Y.L. Zhao, and F.J. Li Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial Lancet 375 2010 56 66
29. E. Plennevaux, E. Sheldon, M. Blatter, M.K. Reeves-Hoche, and M. Denis Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials Lancet 375 2010 41 48
30. F.C. Zhu, H. Wang, H.H. Fang, J.G. Yang, X.J. Lin, X.F. Liang, X.F. Zhang, H.X. Pan, F.Y. Meng, and Y.M. Hu A novel influenza A (H1N1) vaccine in various age groups N Engl J Med 361 2009 2414 2423
31. T. Nolan, J. McVernon, M. Skeljo, P. Richmond, U. Wadia, S. Lambert, M. Nissen, H. Marshall, R. Booy, and L. Heron Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial JAMA 303 2010 37 46
32. E. Plennevaux, M. Blatter, M.J. Cornish, K. Go, D. Kirby, M. Wali, M.K. Reeves-Hoche, and M. Denis Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial Vaccine 29 2011 1569 1575
33. G.L. Chen, Y.F. Lau, E.W. Lamirande, A.W. McCall, and Subbarao K Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine Proc Natl Acad Sci USA 108 2011 1140 1145
34. I. Leroux-Roels, R. Bernhard, P. Gerard, M. Drame, E. Hanon, and G. Leroux-Roels Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine PLoS ONE 3 2008 e1665
35. I. Leroux-Roels, A. Borkowski, T. Vanwolleghem, M. Drame, F. Clement, E. Hons, J.M. Devaster, and G. Leroux-Roels Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial Lancet 370 2007 580 589 (Pubitemid 47247854)
36. W.T. Walker, and S.N. Faust Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine Expert Rev Vaccines 9 2010 1385 1398
37. T.W. Clark, M. Pareek, K. Hoschler, H. Dillon, K.G. Nicholson, N. Groth, and I. Stephenson Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine N Engl J Med 361 2009 2424 2435
38. K.G. Nicholson, K.R. Abrams, S. Batham, T.W. Clark, K. Hoschler, W.S. Lim, M.J. Medina, J.S. Nguyen-Van-Tam, R.C. Read, and F.C. Warren Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial Lancet Infect Dis 11 2011 91 101
39. F. Roman, T. Vaman, F. Kafeja, E. Hanon, and P. Van Damme AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age Clin Infect Dis 51 2010 668 677
40. A. Carmona, F. Omenaca, J.C. Tejedor, J.M. Merino, T. Vaman, I. Dieussaert, P. Gillard, and J. Aristegui Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months Vaccine 28 2010 5837 5844
41. S. Esposito, L. Pugni, C. Daleno, A. Ronchi, A. Valzano, D. Serra, F. Mosca, and N. Principi Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months Pediatrics 127 2011 e1161 e1168
42. C.S. Waddington, W.T. Walker, C. Oeser, A. Reiner, T. John, S. Wilkins, M. Casey, P.E. Eccleston, R.J. Allen, and I. Okike Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study BMJ 340 2010 c2649
43. D. Butler Regulators face tough flu-jab choices Nature 460 2009 446
44. Z. Chen, W. Wang, H. Zhou, A.L. Suguitan Jr., C. Shambaugh, L. Kim, J. Zhao, G. Kemble, and H. Jin Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs J Virol 84 2010 44 51
45. R.M. Mallory, E. Malkin, C.S. Ambrose, T. Bellamy, L. Shi, T. Yi, T. Jones, G. Kemble, and F. Dubovsky Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials PLoS ONE 5 2010 e13755
46. K.M. Edwards, W.D. Dupont, M.K. Westrich, W.D. Plummer Jr., P.S. Palmer, and P.F. Wright A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease J Infect Dis 169 1994 68 76
47. J.J. Treanor, K. Kotloff, R.F. Betts, R. Belshe, F. Newman, D. Iacuzio, J. Wittes, and M. Bryant Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses Vaccine 18 1999 899 906
48. C. Vellozzi, K.R. Broder, P. Haber, A. Guh, M. Nguyen, M. Cano, P. Lewis, M.M. McNeil, M. Bryant, and J. Singleton Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010 Vaccine 28 2010 7248 7255
49. Y. Dauvilliers, J. Montplaisir, V. Cochen, A. Desautels, M. Einen, L. Lin, M. Kawashima, S. Bayard, C. Monaca, and M. Tiberge Post-H1N1 narcolepsy-cataplexy Sleep 33 2010 1428 1430
50. J.L. Montastruc, G. Durrieu, and O. Rascol Pandemrix degrees, (H1N1)v influenza and reported cases of narcolepsy Vaccine 29 2010
51. J. Zarocostas WHO backs further probes into possible link between H1N1 vaccine and narcolepsy in children BMJ 342 2011 d909
52. T.F. Tsai, A. Crucitti, P. Nacci, U. Nicolay, G.D. Cioppa, J. Ferguson, and R. Clemens Explorations of clinical trials and pharmacovigilance databases of MF59((R))-adjuvanted influenza vaccines for associated cases of narcolepsy Scand J Infect Dis 2011
53. P. Bryan, and S. Seabroke No increased risk of febrile convulsions after seasonal influenza immunisation in UK Lancet 377 2011 904
54. M. Valenciano, E. Kissling, J.M. Cohen, B. Oroszi, A.S. Barret, C. Rizzo, B. Nunes, D. Pitigoi, A. Larrauri Camara, and A. Mosnier Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study PLoS Med 8 2011 e1000388
55. P. Hardelid, D.M. Fleming, J. McMenamin, N. Andrews, C. Robertson, P. SebastianPillai, J. Ellis, W. Carman, T. Wreghitt, and J.M. Watson Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010 Euro Surveill 2011 16
56. J.Y. Song, H.J. Cheong, J.Y. Heo, J.Y. Noh, W.S. Choi, D.W. Park, J. Lee, H.W. Jeong, S.Y. Kee, and W.J. Kim Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea Vaccine 29 2011 1395 1398
57. J. Wu, F. Xu, L. Lu, M. Lu, L. Miao, T. Gao, W. Ji, L. Suo, D. Liu, and R. Ma Safety and effectiveness of a 2009 H1N1 vaccine in Beijing N Engl J Med 363 2010 2416 2423
58. E. Kissling, and M. Valenciano Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study Euro Surveill 2011 16
59. R. Pebody, P. Hardelid, D. Fleming, J. McMenamin, N. Andrews, C. Robertson, D. Thomas, P. Sebastianpillai, J. Ellis, and W. Carman Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11 Euro Surveill 2011 16
60. C. Savulescu, S. Jimenez-Jorge, S. de Mateo, J. Ledesma, F. Pozo, I. Casas, and A. Larrauri Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case-control study Euro Surveill 2011 16